Ironwood Pharmaceuticals, Inc. (IRWD)
IRWD Stock Price Chart
Explore Ironwood Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze IRWD price movements and trends.
IRWD Company Profile
Discover essential business fundamentals and corporate details for Ironwood Pharmaceuticals, Inc. (IRWD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Feb 2010
Employees
253.00
Website
https://www.ironwoodpharma.comCEO
Thomas A. McCourt
Description
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
IRWD Financial Timeline
Browse a chronological timeline of Ironwood Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.26, while revenue estimate is $116.97m.
Earnings released on 7 May 2026
EPS came in at $0.24 surpassing the estimated $0.07 by +242.86%, while revenue for the quarter reached $106.51m , beating expectations by +15.63%.
Earnings released on 25 Feb 2026
EPS came in at -$0.01 falling short of the estimated $0.02 by -150.00%, while revenue for the quarter reached $47.71m , missing expectations by -6.30%.
Earnings released on 10 Nov 2025
EPS came in at $0.24 surpassing the estimated $0.09 by +166.67%, while revenue for the quarter reached $122.06m , beating expectations by +139.65%.
Earnings released on 7 Aug 2025
EPS came in at $0.14 surpassing the estimated -$0.02 by +800.00%, while revenue for the quarter reached $85.24m , beating expectations by +9.53%.
Earnings released on 7 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.05 by -180.00%, while revenue for the quarter reached $41.14m , missing expectations by -42.08%.
Earnings released on 27 Feb 2025
EPS came in at $0.02 falling short of the estimated $0.10 by -80.00%, while revenue for the quarter reached $90.55m , beating expectations by +35.10%.
Earnings released on 7 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.08 by -75.00%, while revenue for the quarter reached $91.59m , missing expectations by -0.96%.
Earnings released on 8 Aug 2024
EPS came in at -$0.01 falling short of the estimated $0.15 by -103.61%, while revenue for the quarter reached $94.40m , missing expectations by -11.78%.
Earnings released on 9 May 2024
EPS came in at -$0.02 falling short of the estimated $0.18 by -111.11%, while revenue for the quarter reached $74.88m , missing expectations by -29.23%.
Earnings released on 15 Feb 2024
EPS came in at -$0.01 falling short of the estimated $0.21 by -104.76%, while revenue for the quarter reached $117.55m , beating expectations by +0.06%.
Earnings released on 9 Nov 2023
EPS came in at $0.09 falling short of the estimated $0.16 by -43.75%, while revenue for the quarter reached $113.74m , beating expectations by +0.75%.
Earnings released on 8 Aug 2023
EPS came in at $0.31 surpassing the estimated $0.25 by +24.00%, while revenue for the quarter reached $107.38m , beating expectations by +3.54%.
Earnings released on 4 May 2023
EPS came in at $0.25 surpassing the estimated $0.24 by +4.17%, while revenue for the quarter reached $104.06m , beating expectations by +3.64%.
Earnings released on 16 Feb 2023
EPS came in at $0.27 matching the estimated $0.27, while revenue for the quarter reached $107.20m , missing expectations by -0.78%.
Earnings released on 3 Nov 2022
EPS came in at $0.28 surpassing the estimated $0.27 by +3.70%, while revenue for the quarter reached $108.64m , missing expectations by -0.47%.
Earnings released on 4 Aug 2022
EPS came in at $0.21 falling short of the estimated $0.30 by -30.00%, while revenue for the quarter reached $97.23m , missing expectations by -6.10%.
Earnings released on 5 May 2022
EPS came in at $0.21 falling short of the estimated $0.26 by -19.23%, while revenue for the quarter reached $97.53m , beating expectations by +0.94%.
Earnings released on 17 Feb 2022
EPS came in at $0.27 falling short of the estimated $0.35 by -22.86%, while revenue for the quarter reached $117.13m , beating expectations by +6.31%.
Earnings released on 4 Nov 2021
EPS came in at $0.33 surpassing the estimated $0.31 by +6.45%, while revenue for the quarter reached $103.75m , missing expectations by -2.51%.
Earnings released on 5 Aug 2021
EPS came in at $0.34 surpassing the estimated $0.23 by +47.83%, while revenue for the quarter reached $104.03m , meeting expectations.
IRWD Stock Performance
Access detailed IRWD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
